Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
RESEARCH TOOLSreports
| Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 95.00K | $ 243.00K | $ 38.49M | $ 0.00 | $ 0.00 |
| Gross Profit | $ -242.82M | $ -16.48M | $ 25.42M | $ -11.54M | $ -5.03M |
| Operating Income | $ -327.74M | $ -335.45M | $ -255.79M | $ -258.24M | $ -202.01M |
| EBITDA | $ -300.29M | $ -321.24M | $ -169.74M | $ -250.81M | $ -179.90M |
| Net Income | $ -327.26M | $ -329.81M | $ -244.84M | $ -233.47M | $ -184.59M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 448.70M | $ 576.47M | $ 809.48M | $ 1.03B | $ 588.86M |
| Total Assets | $ 642.84M | $ 817.08M | $ 1.04B | $ 1.23B | $ 717.80M |
| Total Debt | $ 95.12M | $ 95.12M | $ 69.93M | $ 53.78M | $ 51.35M |
| Net Debt | $ 11.97M | $ -481.35M | $ -739.55M | $ -978.34M | $ -537.51M |
| Total Liabilities | $ 130.60M | $ 151.21M | $ 122.23M | $ 148.21M | $ 88.78M |
| Stockholders' Equity | $ 512.23M | $ 665.87M | $ 916.41M | $ 1.08B | $ 629.02M |
| Cash Flow | |||||
| Free Cash Flow | $ -239.25M | $ -225.71M | $ -206.26M | $ -181.05M | $ -188.14M |
| Operating Cash Flow | $ -237.73M | $ -220.52M | $ -184.81M | $ -115.09M | $ -137.35M |
| Investing Cash Flow | $ 163.29M | $ 106.16M | $ 163.66M | $ -505.12M | $ 164.08M |
| Financing Cash Flow | $ 95.69M | $ 2.95M | $ 11.96M | $ 633.59M | $ 58.96M |